Cargando…
Identifying treatment response to antihypertensives in patients with obesity-related hypertension
BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654008/ https://www.ncbi.nlm.nih.gov/pubmed/29085669 http://dx.doi.org/10.1186/s40885-017-0077-x |
_version_ | 1783273322723672064 |
---|---|
author | Schrover, Ilse M. Dorresteijn, Jannick A. N. Smits, Jodine E. Danser, A. H. Jan Visseren, Frank L. J. Spiering, Wilko |
author_facet | Schrover, Ilse M. Dorresteijn, Jannick A. N. Smits, Jodine E. Danser, A. H. Jan Visseren, Frank L. J. Spiering, Wilko |
author_sort | Schrover, Ilse M. |
collection | PubMed |
description | BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. RESULTS: Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (−21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (−15 mmHg versus −7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was −13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. CONCLUSION: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. TRIAL REGISTRATION: NCT01138423. Registered June 4th, 2010. |
format | Online Article Text |
id | pubmed-5654008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56540082017-10-30 Identifying treatment response to antihypertensives in patients with obesity-related hypertension Schrover, Ilse M. Dorresteijn, Jannick A. N. Smits, Jodine E. Danser, A. H. Jan Visseren, Frank L. J. Spiering, Wilko Clin Hypertens Research BACKGROUND: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. METHODS: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. RESULTS: Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (−21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (−15 mmHg versus −7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was −13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. CONCLUSION: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. TRIAL REGISTRATION: NCT01138423. Registered June 4th, 2010. BioMed Central 2017-10-24 /pmc/articles/PMC5654008/ /pubmed/29085669 http://dx.doi.org/10.1186/s40885-017-0077-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Schrover, Ilse M. Dorresteijn, Jannick A. N. Smits, Jodine E. Danser, A. H. Jan Visseren, Frank L. J. Spiering, Wilko Identifying treatment response to antihypertensives in patients with obesity-related hypertension |
title | Identifying treatment response to antihypertensives in patients with obesity-related hypertension |
title_full | Identifying treatment response to antihypertensives in patients with obesity-related hypertension |
title_fullStr | Identifying treatment response to antihypertensives in patients with obesity-related hypertension |
title_full_unstemmed | Identifying treatment response to antihypertensives in patients with obesity-related hypertension |
title_short | Identifying treatment response to antihypertensives in patients with obesity-related hypertension |
title_sort | identifying treatment response to antihypertensives in patients with obesity-related hypertension |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654008/ https://www.ncbi.nlm.nih.gov/pubmed/29085669 http://dx.doi.org/10.1186/s40885-017-0077-x |
work_keys_str_mv | AT schroverilsem identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension AT dorresteijnjannickan identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension AT smitsjodinee identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension AT danserahjan identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension AT visserenfranklj identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension AT spieringwilko identifyingtreatmentresponsetoantihypertensivesinpatientswithobesityrelatedhypertension |